Skip to the stories
Mental Health

ESMO 2026: Personalised Melanoma Vaccine and Promising New Cancer Drugs

By Tim Gunn 515 views

Early ESMO 2026 results point to a personalised melanoma vaccine, targeted radiotherapy for lung cancer and new drugs for womb, stomach and bladder cancers.

ESMO 2026: Personalised Melanoma Vaccine and Promising New Cancer Drugs

Cancer researchers met in Madrid from 23 to 27 October for the European Society for Medical Oncology (ESMO) annual conference, and the headline result is a personalised vaccine for melanoma. The rest of the programme leaned toward refined radiotherapy and a new generation of antibody-drug conjugates. Most of the findings come from ongoing studies, so they're promising signals rather than settled practice. Here's what's actually new, how strong the evidence looks, and what would need to happen before any of it reaches routine care.

A computer graphic showing faint microbes against a pink background.

A personalised vaccine that lowers the risk of melanoma returning

The most anticipated result came out before the conference opened. The Phase 3 INTerpath-001 trial tested an mRNA vaccine called intismeran autogene alongside a standard immunotherapy drug in people with advanced melanoma skin cancer. Over two years, the combination cut the risk of dying or having the cancer return by 42%, compared with immunotherapy alone.

That's the first Phase 3 result of its kind, and it's a meaningful step. Still, the trial is only part of the story. Researchers gave the vaccine to people with stage 2, 3 or 4 melanoma that had been surgically removed but carried a high risk of coming back. That's a specific group, and the trial will keep running so the team can see how well the treatment holds up over longer periods and whether it extends overall survival. That overall survival question is the one that matters most for patients, and it isn't answered yet.

Man wearing black socks and grey joggers on a glass digital scale with 116.6 kg displayed

Dr Catherine Elliott, Cancer Research UK's director of research, put it this way: "The science that helped protect us against COVID-19 is now showing promise in treating cancer. These results are encouraging for people with melanoma, a cancer that can come back aggressively after surgery."

How an mRNA cancer vaccine is built

Despite the shared name, no two intismeran vaccines are identical. Scientists test each patient's cancer cells for unique features the immune system can learn to recognise. A computer algorithm then helps design the final vaccine, which carries mRNA instructions for spotting those features on any cancer cells that remain or return.

A pill in a petri dish. The Pill is transparent but contains a compressed black sponge. There is a light blue thread attached to one end.

Patients receive the personalised vaccine alongside pembrolizumab, an immunotherapy drug that releases the brakes on immune cells that attack cancer. A useful way to picture it: the immunotherapy is the engine and the vaccine helps the immune system find its target.

The technology overlaps with some COVID-19 vaccines, but the purpose is entirely different. This is a treatment given after surgery, not a preventive shot for healthy people. That distinction matters for how the public understands it, because the personalisation also makes manufacturing slow and costly. Each vaccine is made for one person, which is a big reason experts are cautious about how quickly it could scale.

Lung cancer cells seen through a microscope, in shades of purple and green,

There's also a limit on how far these results can travel. Melanoma already responds relatively well to immunotherapy, so success here won't automatically carry over to cancers where immunotherapy works less well. Each cancer type will need its own evidence.

Targeted radiotherapy adds months for some people with advanced lung cancer

Not every headline was about new molecules. The Phase 2 SARON trial, funded by Cancer Research UK and sponsored by University College London, asked whether a more precise form of radiotherapy could help people with advanced lung cancer. The people in question have non-small cell lung cancer (NSCLC) that has spread beyond the lungs, but only to a small number of other areas.

A computer analysis of glioblastoma cells, which are labelled in different colours.

Doctors usually treat this group with therapies that work throughout the body, such as chemotherapy, immunotherapy or a combination of the two. In SARON, researchers added local consolidation radiotherapy, which targets the tumours and affected lymph nodes, to those standard treatments. The trial enrolled 70 patients from 19 hospitals across the UK.

At the three-year follow-up, patients who received the radiotherapy went 56% longer without their cancer growing or spreading. On average, their disease stayed stable for 13.9 months before progressing, compared with 8.9 months for those on standard treatment alone. It's a clear difference, but a Phase 2 study with 70 people is small, so it's a reason for a larger trial rather than a change in practice.

Prostate Cancer cell image taken using a Scanning Electron Microscope

The practical angle is what makes this one worth watching. The radiotherapy technique is already available on the NHS, so if later trials confirm the benefit, the path to wider use could be shorter than for a new drug. Dr Dani Skirrow, a science engagement manager at Cancer Research UK, said the findings give people "precious time to carry on doing the things that matter to them with their loved ones."

The technique in question is a type of stereotactic radiotherapy, sometimes called SABR, SRT or SBRT. It delivers high doses to small areas while sparing nearby healthy tissue, which is especially important near the lungs and heart. NHS England has also begun using SABR to shorten treatment for some men with early-stage prostate cancer, so the method is already moving into routine use in other settings.

The Francis Crick Institute building with foliage visible in foreground on a sunny day.

A new antibody-drug conjugate for advanced womb cancer

Sacituzumab tirumotecan, usually shortened to sac-TMT, belongs to a class called antibody-drug conjugates (ADCs). The name describes the design: an antibody acts as a homing device that finds cancer cells, and it carries a chemotherapy payload directly to them. Standard chemotherapy hits fast-dividing cells across the body. An ADC aims to concentrate the drug where it's needed.

In the Phase 3 TroFuse-005 study, published in The Lancet, women with advanced or recurrent endometrial cancer, the most common type of womb cancer, received sac-TMT. These women had already had chemotherapy and immunotherapy, a group with very few remaining options when the disease resists or returns after standard treatment.

Clinical trial

Compared with further rounds of chemotherapy, women on sac-TMT had a 41% lower risk of their cancer growing or spreading. Their risk of death was 32% lower. Treatment also shrank tumours in 35% of women, compared with 17% on chemotherapy, which is more than double the response rate.

The side effects need equal attention. A higher proportion of people on sac-TMT had serious adverse events linked to treatment, although the most common side effects were described as manageable. Dr Elliott called the results promising and said the drug "can reduce the risk of death by nearly a third for some patients." She added that if it's approved for NHS use, it could become a vital new option. That's a big if, and the timeline depends on the approval process that follows trial publication.

Woman waiting in hospital waiting room

Early signs that sac-TMT could also help lung cancer

Sac-TMT showed up in a second setting at ESMO. In the OptiTROP-Lung06 study, run in China, researchers combined it with immunotherapy as a first treatment for a type of advanced lung cancer. The population was people whose tumours were unlikely to respond to immunotherapy on its own.

The interim analysis found an average of almost 15 months before the cancer grew again or the patient died. That's nearly 10 months longer than patients treated with chemotherapy and immunotherapy. People on the new combination also had fewer severe side effects.

A crowd of people walking away from the camera down a busy street

Interim results from a single-country study can shift as more data arrives, and the trial still has time to run. The global TroFuse007 trial is testing the same combination in a more diverse group of patients, which will show whether the benefit travels beyond the original population.

A new option for stomach and gastro-oesophageal cancers

Researchers from China and Japan reported that a different ADC, arcotatug tavatecan, may slow some advanced stomach (gastric) and gastro-oesophageal cancers once standard options have stopped working. The data come from an interim analysis of the Phase 3 G-HOPE-001 trial.

An man in a blue shirt and jeans applying squeezing sunscreen into his hand from a bottle.

Patients on arcotatug tavatecan lived an average of three months longer than those on other approved drugs in the trial. In almost 4 in 10 patients whose previous treatments had failed, the drug shrank tumours. The comparator drugs shrank tumours in fewer than 1 in 10. The time before the cancer started growing again also lengthened. The drug targets cells with high levels of Claudin 18.2, a protein especially common in cancers of the stomach.

The researchers also reported a slightly lower rate of severe side effects than the other drugs in the study. Dr Graham Cadwallader, Cancer Research UK's head of clinical research, noted that people with advanced stomach cancer "can feel they've run out of road when treatments stop working," and that the results point toward another option. He was also clear about what's missing: "We now need to understand whether these benefits last and extend to a wider range of people beyond China and Japan."

A separate global study, the Phase 3 CLARITY-Gastric01 trial, looked at a related approach, sonesitatug vedotin. That drug delivers a different chemotherapy to cells with Claudin 18.2. It included patients with lower levels of the protein and was reported to reduce some people's risk of dying from advanced stomach and oesophageal cancers that had stopped responding to other treatments. Taken together, the Claudin 18.2 work suggests this target is becoming a serious focus in stomach cancer.

Combining targeted drugs to outpace resistance in lung cancer

The Phase 3 SAFFRON trial tested a way around one of the most common problems in targeted lung cancer treatment. Scientists in the 1980s, including Cancer Research UK-funded researchers, identified the protein EGFR as a driver of cancer growth, and that discovery led to today's EGFR-blocking drugs. Over time, though, tumours can learn to resist those drugs. One common escape route involves cells switching to a second protein, MET, to keep growing.

SAFFRON combined the EGFR-targeting drug osimertinib with savolitinib, a MET-blocking drug. The patients had advanced NSCLC showing signs that MET was helping their tumours resist osimertinib alone. Blocking both proteins at once kept some tumours from growing for longer than chemotherapy did. Patients on the combination had an average of two more months before their cancer grew again, and five extra months overall. They were also less likely to have severe side effects.

The broader lesson is about timing. Genetic testing of a tumour can guide treatment not just at diagnosis but whenever the disease changes course. Here's the thing: resistance is a moving target, and tests that track it may matter as much as the first drug choice.

Head and neck cancer and the case for a broader approach

Sometimes one drug can attack a tumour from more than one direction. In a trial led by UK researchers, amivantamab, an antibody that blocks both EGFR and MET and also stimulates the immune system, shrank tumours in almost 8 out of 10 patients with a hard-to-treat type of head and neck cancer. The NHS already uses amivantamab for NSCLC, given by injection.

This was an early-phase study, part of the OrigAMI-4 trial, and it included a small group of people whose head and neck cancers had returned or spread and weren't linked to high-risk HPV infection. Those cancers tend to have worse outcomes, and treatment has historically been the same for all head and neck cancers. In OrigAMI-4, adding amivantamab to immunotherapy and chemotherapy more than doubled the proportion of patients whose tumours shrank. The Phase 3 OrigAMI-5 trial will now test the approach in a larger group. Researchers from the Institute of Cancer Research and the Royal Marsden NHS Trust took part in the UK study.

An alternative to cisplatin for muscle-invasive bladder cancer

Before surgery for muscle-invasive bladder cancer (MIBC), doctors often give cisplatin-based chemotherapy to lower the risk of the cancer returning. For almost half of patients, though, that isn't possible because of age, poor kidney function or other health conditions. Without the treatment, those patients face a higher risk of recurrence.

The Phase 3 VOLGA trial tested an alternative. Patients who were ineligible for cisplatin or had declined it received the immunotherapy durvalumab together with the ADC enfortumab vedotin. They had three cycles of both drugs before surgery, followed by nine cycles of durvalumab afterwards.

Those patients lived longer and had a higher overall survival rate than those who had surgery alone, with survival at 78% compared with 69%. They were also half as likely to experience certain complications or events, including the cancer returning. Along with other trials reported earlier this year, the findings suggest more options could soon be available for this group. My read is that bladder cancer is becoming one of the clearest examples of ADCs moving from a second-line idea into the early treatment setting, though the final shape of that change will depend on longer follow-up.

What to watch next, and when to talk to a doctor

Most of what ESMO showed is at the interim or early stage. The melanoma vaccine needs overall survival data. The radiotherapy result needs a larger trial. The ADCs need longer follow-up, more diverse populations and, in many cases, regulatory review before they could be used in routine care. Those steps take years, and some results will change as trials mature.

For readers managing their own health or supporting someone else, the practical takeaway is simple. These are research findings, not new recommendations, and none of them should prompt changes to treatment on their own. If you or a family member has one of these cancers, the most useful step is a conversation with the oncology team about which trials are open, what options exist now and what the evidence means for your specific situation. A pharmacist can also help with questions about how any therapy fits alongside other medicines.

Source: Tim Gunn · news.cancerresearchuk.org

From the same basket